Michelle Laflamme is the founder, president, and CEO of Emovi, Inc., a medical device company that developed the KneeKG, the first in-clinic device that meets the global need for identifying and quantifying knee biomechanical dysfunctions causing knee pain and symptoms. Michelle has more than 20 years of experience in business and commercial development in life sciences, particularly in biopharmaceuticals and medical devices. In 2008, she received First Prize in the Technological and Technical Innovations category from the Québec Entrepreneurship Contest. With the support of PME Mtl, Desjardins Group, the City of Montreal, and the Quebec Government, she formed the CTS Health Technology, an organization dedicated to helping medical businesses market innovative medical products. In 2009, Michelle was a finalist in Ernst & Young's Entrepreneur of the Year® competition. Michelle is Chairman and member of the Board of Directors of PME Mtl Centre-Est, an organization dedicated to supporting entrepreneurs, and is a member of the Board of Directors of MEDTEQ, an industrial research and innovation consortium in medical technologies in Quebec. She was recently appointed administrator of Axelys, a new company set up by the Quebec Government to accelerate the commercialization of innovations. She also sits on the entrepreneurship action table in Laval and Montreal and is actively involved in Réseau Mentorat to support entrepreneurs. Prior to Emovi, Michelle served as Vice President, Business Development of ProMetic Life Sciences, a biopharmaceutical company, where she led private and public funding, clinched strategic alliances and agreements with partners of international scope for the development and commercialization of products. Michelle has a Master of Laws from Université de Montréal and is a member of the Barreau du Quebec.